Professor
University of London, United Kingdom
Nicholas James, MBBS, PhD, is Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research and the Royal Marsden Hospital, London, UK. He completed degrees in medicine and immunology at the University of London and went on to earn a PhD in cell cycle biology from Imperial College, London, UK. He is an NIHR Senior Investigator and Deputy Dean of the Institute of Cancer Research.
The research of Prof. James focuses on advanced prostate cancer and bladder preservation strategies for locally advanced bladder cancer. He is the Chief Investigator of the STAMPEDE trial, a landmark study evaluating ten different therapies for advanced prostate cancer, involving 12,000 men – the findings have had a global impact on clinical practice. The STAMPEDE trial now continues as STAMPEDE2 with two new comparisons. Additionally, he has led trials demonstrating that low-dose synchronous chemotherapy can significantly reduce invasive bladder cancer relapse rates, as published in The New England Journal of Medicine.
From 2020-2024 he chaired a Commission on Prostate Cancer for the Lancet, making broad recommendations for future policy on prostate cancer care globally. He has also published extensively on health inequalities and practical ways to address these via the Man Van project.
B2B-04: The role of metformin plus ADT in mHSPC – a STAMPEDE update
Friday, October 31, 2025
15:50 - 16:05 GMT+0